Apple Tree Partners
VC Fund
New York, United States
Apple Tree Partners is a VC fund in New York focused on Biotechnology and Health Care. ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
- Total investments:
- 95
- Last investment:
- Lead investor:
- 63%
- Fund size:
- $1B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Apple Tree Partners invests in
Stages Apple Tree Partners invests in
Countries Apple Tree Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 33 contacts → | |||
Round size
- Seed
- $3.5M–$8M
- Series A
- $20M–$75M
- Series B
- $29M–$100M
Investment Focus
Industry
- Biotechnology 31 (33%)
- Health Care 24 (25%)
- Therapeutics 13 (14%)
- Medical 11 (12%)
- Medical Device 8 (8%)
Stage
- Series A 20 (21%)
- Series B 11 (12%)
- Seed 8 (8%)
- Series C 4 (4%)
- Venture - Series Unknown 4 (4%)
Country
- United States 35 (37%)
- Canada 3 (3%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexander McCampbell
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Andrew Bayliffe
Venture Partner
|
Venture Partner | Total investments: 2 | Find email | |
Anna Batarina
Partner
|
Partner | Total investments: 0 | Find email | |
Brian Vash
Entrepreneur in Residence
|
Entrepreneur in Residence | Total investments: 0 | Find email | |
Daniel Finkelman
General Counsel
|
General Counsel | Total investments: 0 | Find email | |
| See all 33 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Red Queen Therapeutics is a biotech company that works in the fields of medicine, agriculture, crop production, non-food use of crops, and heavy industry. They generally research, develop, and produce a variety of commercial products while most focus on either medical or agricultural applications. | $55M / Series A / Aug 06, 2024 | ||
| Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen. | $52M / Series A / Dec 14, 2023 | ||
| Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy. | $40M / Series A / Nov 08, 2023 | ||
| Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.Their initial clinical candidate, AU-007, stands apart from existing IL-2 therapeutics by introducing a novel approach that addresses a significant medical challenge of the present era: the eradication of cancer. Throughharnessing the anti-cancer potential of interleukin-2, they are breaking down barriers in the field of immuno-oncology. Their distinctive immunotherapy, computationally designed to precisely guide the immune system in attacking tumor cells, is poised to make a substantial impact. | $20M / Series A / Aug 01, 2023 | ||
Initial Therapeutics
|
Initial Therapeutics is a company located in New York, New York. | $75M / Series A / May 01, 2023 | |
| Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations. | $30M / Series A / Jan 09, 2023 | ||
| Apertor is discovering and developing new treatments for age-related diseases. | Venture - Series Unknown / Jan 01, 2023 | ||
| Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy. | $50M / Series A / Oct 11, 2022 | ||
| Galvanize Therapeutics is an energy-based medical device technology that provides therapeutic products and services to deliver healthcare solutions. The company aims to become the global leader in delivering medical technology innovations that drive biological processes to treat a range of diseases, starting with treating chronic bronchitissymptoms, cardiac arrhythmias, and solid tumors.It was formed by Apple Tree Partners in 2022. | $100M / Series B / Sep 15, 2022 | ||
Marlinspike Therapeutics
|
Marlinspike Therapeutics is a biotechnology company. The company was founded in 2021 and is headquartered in Cambridge, Massachusetts, United States. | $3.5M / Seed / Feb 28, 2022 | |
| See all 95 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Apple Tree Partners invest in?
Apple Tree Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 95 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Apple Tree Partners's check size?
Apple Tree Partners typically joins rounds of $3.5M–$8M at Seed, $20M–$75M at Series A and $29M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Apple Tree Partners participates in.
How do I contact Apple Tree Partners?
Public channels for Apple Tree Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Apple Tree Partners?
The team at Apple Tree Partners includes Alexander McCampbell (Venture Partner), Andrew Bayliffe (Venture Partner) and Anna Batarina (Partner), among 33 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
